LAP leaps into the future with collaboration and innovation

At this year's ASTRO 2023 annual meeting, LAP introduced not only its newest addition to the product portfolio, LUNA 3D, but also LAP Plus – a patient-centric ecosystem. By collaborating with partners worldwide, LAP Plus aims to integrate solutions and empower clinicians to bridge the gap between quality assurance and patient treatment. Thomas Simmerer, CEO of LAP GmbH Laser Applikationen: “Our goal is to enhance individualized patient care, deliver advanced decision-support capabilities, and ensure efficient and accessible cancer care with improved patient safety.”

One specific collaboration showcased at ASTRO is CNERGY Go!, a biometric patient identification solution from Cablon Medical B.V. that fits perfectly to the LUNA 3D setting. Jurjen Weistra, Vice President at Cablon Medical B.V.: “Reliable patient identification is crucial in radiotherapy to ensure the correct treatment dosage and location on the body. CNERGY Go! enhances treatment safety by automating and streamlining patient identification and accessory verification.”

The partnership leverages CNERGY technology to empower clinicians with state-of-the-art support tools committed to automatic patient positioning and seamlessly integrating solutions to deliver maximum value. LAP's commitment to innovation and collaboration underscores its dedication to advancing the field of radiotherapy by providing healthcare professionals with clinical tools that improve patient care.

LUNA 3D is 510(k) pending (K232031) – not available for sale in the US. Availability of products, features, and services may vary depending on your location.

Cablon Medical’s Patient Identification Module (CNERGY Go!) is a Class I Medical Device and in compliance with the European Medical Device Regulations, MDR (EU) 2017/745, and the US (FDA) regulatory requirements. Availability in other countries may vary depending on the local regulatory requirement of the country. For more information, please visit Cablon.nl